{"id":831880,"date":"2025-03-31T17:19:46","date_gmt":"2025-03-31T21:19:46","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-participate-in-april-2025-investor-conferences\/"},"modified":"2025-03-31T17:19:46","modified_gmt":"2025-03-31T21:19:46","slug":"revolution-medicines-to-participate-in-april-2025-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-participate-in-april-2025-investor-conferences\/","title":{"rendered":"Revolution Medicines to Participate in April 2025 Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">REDWOOD CITY, Calif., March  31, 2025  (GLOBE NEWSWIRE) &#8212; Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company\u2019s chief executive officer and chairman, will participate in in two upcoming investor conferences.<\/p>\n<p align=\"justify\">Details of the company\u2019s participation are as follows:<\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">\n          <strong>Needham 24<\/strong><br \/>\n          <sup><br \/>\n            <strong>th<\/strong><br \/>\n          <\/sup><br \/>\n          <strong> Annual Virtual Healthcare Conference<\/strong><\/p>\n<ul type=\"circle\">\n<li style=\"text-align:justify\">Fireside Chat: Monday, April 7 at 2:15 p.m. ET<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">\n          <strong>Stifel 2025 Virtual Targeted Oncology Forum<\/strong><\/p>\n<ul type=\"circle\">\n<li style=\"text-align:justify\">Fireside Chat: Wednesday, April 9 at 1:00 p.m. ET<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>To listen to a live webcast of any of these events, or access archived webcasts, please visit:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=dIkG1JlpQZDtJcQ-jIJwkWw16zlyI7ebMJRixjpodXWyI_JFDtHOfZmFUwvtqpFI8AG8e0tWr2fWkl0BZF1MkOhwcEwtUMmghT18we-ct81WMz_pr-1qN9_XzQ_S96862HFRV8E0JpJ5K5fAfot65iHdz5-uBFALDcVCtSls5VYV7KehKFFGAPch79P8b-K7q2GevBE1gqe1EHuw9sAQ0d5QPBOUZqo4NqxPjCVLzqqU5gkYAG17eeKBysA77wpB4yeFiYr9ewFx7GkpkJ7l9GFFPpiYPmhsOLL24PzhQjT1FZoqhTV-pLAnKk_zvblQ9NkJSlgEtF-f6BVbjjmBYWnn9F2hh3cVEbSIsJd0oVf-umOdxdsNKF82QrtVOWTK\" rel=\"nofollow\" target=\"_blank\">https:\/\/ir.revmed.com\/events-and-presentations<\/a>. Following the live webcasts, replays will be available on the company\u2019s website for at least 14 days.<\/p>\n<p align=\"justify\">\n        <strong>About Revolution Medicines, Inc.<\/strong><br \/>\n        <br \/>Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company\u2019s R&amp;D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company\u2019s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are currently in clinical development. The company anticipates that RMC-5127, a RAS(ON) G12V-selective inhibitor, will be its next RAS(ON) inhibitor to enter clinical development. Additional development opportunities in the company\u2019s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=sVvdcP2YtqX2BJzlzWKvbPR1YEQTy6YGWIF_6aKc4q0GZilWDlE3JoR_MoY3u2tuVy6jetEi0TNPWVhrkmBo9Xu0yUZpEVFimhbgka1iIdsaskw1wy1a2s9p88sS5cn0bE6Rmt04Yt1UPkfrlw7K6OBj9e9606ypWKdu1NA5_RANJlbeL2rb7EPM3xTL64UU3e2Pn0rUu9DlK9ye3XOqHJwIYhW1Z3u2G0y_a9p1Nfg=\" rel=\"nofollow\" target=\"_blank\">www.revmed.com<\/a> and follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=O4ZmQrsiofSN9APvyVx32JPo9549YApmiETT21-b7Z-chpKN2iXOjPoofqBp4mV2C0GUAieTVgyE-QHgIrIB9AOZv-DYZ7K966Lul3yycw66kr22ecaAGv7TbN3giSk2MqdV2DqNM0x39RDaYGnME8YpDCilAfGbuLrfUNlxmDTydyAz046CMQv5OpY22akzKODXdD0bEoZFbe-RD6QYpQNtURllvQJppAr9iWQptifLarEecAAEY3CZEBVdzR-gtpPji27lSAkHDHUcq6u3NQ==\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p>\n        <strong>Revolution Medicines Media &amp; Investor Contact:<\/strong><br \/>\n        <br \/>media@revmed.com<br \/>investors@revmed.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMzk5NyM2ODQzMDIwIzIxOTQwMzQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/OTUwZjQwZmQtNmM4Yi00YmJkLWE0NjctNDVmMjMxNmQ5NWMxLTEyMDU1ODctMjAyNS0wMy0zMS1lbg==\/tiny\/Revolution-Medicines-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>REDWOOD CITY, Calif., March 31, 2025 (GLOBE NEWSWIRE) &#8212; Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company\u2019s chief executive officer and chairman, will participate in in two upcoming investor conferences. Details of the company\u2019s participation are as follows: Needham 24 th Annual Virtual Healthcare Conference Fireside Chat: Monday, April 7 at 2:15 p.m. ET Stifel 2025 Virtual Targeted Oncology Forum Fireside Chat: Wednesday, April 9 at 1:00 p.m. ET To listen to a live webcast of any of these events, or access archived webcasts, please visit:\u00a0https:\/\/ir.revmed.com\/events-and-presentations. Following the live webcasts, replays will be available on the company\u2019s website for at &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-participate-in-april-2025-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Revolution Medicines to Participate in April 2025 Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-831880","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Revolution Medicines to Participate in April 2025 Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-participate-in-april-2025-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Revolution Medicines to Participate in April 2025 Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"REDWOOD CITY, Calif., March 31, 2025 (GLOBE NEWSWIRE) &#8212; Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company\u2019s chief executive officer and chairman, will participate in in two upcoming investor conferences. Details of the company\u2019s participation are as follows: Needham 24 th Annual Virtual Healthcare Conference Fireside Chat: Monday, April 7 at 2:15 p.m. ET Stifel 2025 Virtual Targeted Oncology Forum Fireside Chat: Wednesday, April 9 at 1:00 p.m. ET To listen to a live webcast of any of these events, or access archived webcasts, please visit:\u00a0https:\/\/ir.revmed.com\/events-and-presentations. Following the live webcasts, replays will be available on the company\u2019s website for at &hellip; Continue reading &quot;Revolution Medicines to Participate in April 2025 Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-participate-in-april-2025-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-31T21:19:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMzk5NyM2ODQzMDIwIzIxOTQwMzQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-participate-in-april-2025-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-participate-in-april-2025-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Revolution Medicines to Participate in April 2025 Investor Conferences\",\"datePublished\":\"2025-03-31T21:19:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-participate-in-april-2025-investor-conferences\\\/\"},\"wordCount\":278,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-participate-in-april-2025-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxMzk5NyM2ODQzMDIwIzIxOTQwMzQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-participate-in-april-2025-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-participate-in-april-2025-investor-conferences\\\/\",\"name\":\"Revolution Medicines to Participate in April 2025 Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-participate-in-april-2025-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-participate-in-april-2025-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxMzk5NyM2ODQzMDIwIzIxOTQwMzQ=\",\"datePublished\":\"2025-03-31T21:19:46+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-participate-in-april-2025-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-participate-in-april-2025-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-participate-in-april-2025-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxMzk5NyM2ODQzMDIwIzIxOTQwMzQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxMzk5NyM2ODQzMDIwIzIxOTQwMzQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-participate-in-april-2025-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Revolution Medicines to Participate in April 2025 Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Revolution Medicines to Participate in April 2025 Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-participate-in-april-2025-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Revolution Medicines to Participate in April 2025 Investor Conferences - Market Newsdesk","og_description":"REDWOOD CITY, Calif., March 31, 2025 (GLOBE NEWSWIRE) &#8212; Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company\u2019s chief executive officer and chairman, will participate in in two upcoming investor conferences. Details of the company\u2019s participation are as follows: Needham 24 th Annual Virtual Healthcare Conference Fireside Chat: Monday, April 7 at 2:15 p.m. ET Stifel 2025 Virtual Targeted Oncology Forum Fireside Chat: Wednesday, April 9 at 1:00 p.m. ET To listen to a live webcast of any of these events, or access archived webcasts, please visit:\u00a0https:\/\/ir.revmed.com\/events-and-presentations. Following the live webcasts, replays will be available on the company\u2019s website for at &hellip; Continue reading \"Revolution Medicines to Participate in April 2025 Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-participate-in-april-2025-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-31T21:19:46+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMzk5NyM2ODQzMDIwIzIxOTQwMzQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-participate-in-april-2025-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-participate-in-april-2025-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Revolution Medicines to Participate in April 2025 Investor Conferences","datePublished":"2025-03-31T21:19:46+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-participate-in-april-2025-investor-conferences\/"},"wordCount":278,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-participate-in-april-2025-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMzk5NyM2ODQzMDIwIzIxOTQwMzQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-participate-in-april-2025-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-participate-in-april-2025-investor-conferences\/","name":"Revolution Medicines to Participate in April 2025 Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-participate-in-april-2025-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-participate-in-april-2025-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMzk5NyM2ODQzMDIwIzIxOTQwMzQ=","datePublished":"2025-03-31T21:19:46+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-participate-in-april-2025-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-participate-in-april-2025-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-participate-in-april-2025-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMzk5NyM2ODQzMDIwIzIxOTQwMzQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMzk5NyM2ODQzMDIwIzIxOTQwMzQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-participate-in-april-2025-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Revolution Medicines to Participate in April 2025 Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/831880","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=831880"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/831880\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=831880"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=831880"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=831880"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}